Page last updated: 2024-12-05
2-methyl-3-butyn-2-ol
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
2-methyl-3-butyn-2-ol: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 8258 |
| CHEMBL ID | 3185871 |
| MeSH ID | M0064539 |
Synonyms (87)
| Synonym |
|---|
| 2-methyl-3-butyne-2-ol |
| 3-hydroxy-3-methyl-1-butyne |
| 2-methyl-but-3-yn-2-ol |
| 2-propyn-1-ol, 1,1-dimethyl-, carbamate |
| carbavane [russian] |
| 1,1-dimethylpropynol |
| ai3-23121 |
| 2-methylbutyn-3-ol-2 |
| 1-butyn-3-ol, 3-methyl- |
| 3-methyl-butyn-3-ol |
| nsc 523 |
| einecs 204-070-5 |
| alpha,alpha-dimethylpropargyl alcohol |
| 3-methyl-butin-(1)-ol-(3) [german] |
| 2-hydroxy-2-methyl-3-butyne |
| brn 0635746 |
| 2-methyl-2-hydroxy-3-butyne |
| inchi=1/c5h8o/c1-4-5(2,3)6/h1,6h,2-3h |
| 2-methylbut-3-yn-2-ol |
| dimethylacetylenylcarbinol |
| dimethylethynylcarbinol |
| carbavane |
| 2-methyl-2-butynol |
| 2-propyn-1-ol,1-dimethyl-, carbamate |
| dimethylethynylmethanol |
| 1,1-dimethyl-2-propyn-1-ol carbamate |
| nsc-523 |
| nsc523 |
| wln: zvox1uu1&1&1 |
| ethynyldimethylcarbinol |
| 3-methyl-1-butyn-3-ol |
| 1,1-dimethyl-2-propynol |
| 3-butyn-2-ol, 2-methyl- |
| 2-methyl-3-butyn-2-ol |
| dimethylacetylenecarbinol |
| 115-19-5 |
| 1,1-dimethylpropargyl alcohol |
| 3-methylbutynol |
| .alpha.,.alpha.-dimethylpropargyl alcohol |
| 2-methyl-3-butyn-2-ol, 98% |
| 3-methylbut-1-yn-1-ol |
| M0180 |
| AKOS004114613 |
| NCGC00248521-01 |
| dtxsid2021949 , |
| dtxcid701949 |
| tox21_200094 |
| NCGC00257648-01 |
| cas-115-19-5 |
| BBL011368 |
| STL146465 |
| dimethyl ethynyl carbinol |
| ehb904xhkh , |
| unii-ehb904xhkh |
| 3-methyl-butin-(1)-ol-(3) |
| ec 204-070-5 |
| 4-01-00-02229 (beilstein handbook reference) |
| 2-methyl-3-butyn-2-ol [mi] |
| methyl-3-butyn-2-ol, 2- |
| 3-methyl-3-hydroxy-1-butyne |
| 3-hydroxy-3-methyl-1-butine |
| dimethyl propargyl alcohol |
| 2-methylbut-3-in-2-ol |
| 3-methyl-1-butin-3-ol |
| 2-methyl-3 butyne-2-ol |
| 3 -methyl-1-butyne-3-ol |
| 1,1-dimethyl-2-propyn-1-ol |
| 2-methyl 3-butyn 2-ol |
| 3-hydroxy-3-methyl-butyne |
| dimethylethynyl carbinol |
| 2-methyl-3 -butyne-2-ol |
| 2-methyl 3 butyn 2-ol |
| 3-hydroxy-3-methylbutyne |
| 3-methyl-1-butyne-3-ol |
| 2-methyl-3-butin-2-ol |
| 2-methylbutan-3-yn-2-ol |
| 2-methyl-d3-3-butyn-1,1,1-d3-2-ol |
| CHEMBL3185871 |
| mfcd00004467 |
| J-512891 |
| F0001-0282 |
| 2-methyl-3-butyn-2-ol, purum, >=99.0% (gc) |
| Z1245735173 |
| BCP18661 |
| Q209427 |
| AMY3792 |
| EN300-60208 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (2)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 5.6302 | 0.0008 | 17.5051 | 59.3239 | AID1159531 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 27.9459 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 41.98
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (41.98) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||